(Reuters) - LONDON, July 16 - Sanofi-Aventis SA's obesity pill Acomplia faces a tough review from European drug safety experts this week, with data suggesting officials see issues over the drug's link with suicidal thoughts.
The European Medicines Agency safety assessment comes a month after a U.S. advisory panel recommended the drug should not be approved in the world's biggest market because it may increase depression and suicidal thinking.
Read more at Reuters.com Government Filings News
The European Medicines Agency safety assessment comes a month after a U.S. advisory panel recommended the drug should not be approved in the world's biggest market because it may increase depression and suicidal thinking.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment